Most Recent

image: A Dime a Dozen

A Dime a Dozen

By | January 1, 2013

Affordable diagnostic tests tackle the world’s most pressing health problems.

0 Comments

image: Games for Science

Games for Science

By | January 1, 2013

Scientists are using video games to tap the collective intelligence of people around the world, while doctors and educators are turning to games to treat and teach.

7 Comments

image: Genomics-Informed Pathology

Genomics-Informed Pathology

By | January 1, 2013

Twenty-first century lab reports will include test results read by a new breed of pathologist.

1 Comment

image: Year of the Fetus

Year of the Fetus

By | December 18, 2012

2012 saw the birth of a handful of non-invasive genetic prenatal tests, but the young industry faces growing pains as legal and ethical questions loom. 

2 Comments

image: 2012 Multimedia Roundup

2012 Multimedia Roundup

By | December 14, 2012

The science images and videos that captured our attention in 2012

1 Comment

image: Single Patent for EU

Single Patent for EU

By | December 12, 2012

After decades of political wrangling, the European Union is poised to introduce a single patent system to reduce red tape and application costs for researchers and companies.

1 Comment

image: Maggot Medicine

Maggot Medicine

By | December 10, 2012

The healing powers of maggots may lie in their secreted proteins, which restrain the human immune response.

2 Comments

image: Drug Approvals Up

Drug Approvals Up

By | December 7, 2012

The total number of new drugs approved this year ties last year for the highest since 2004, suggesting that the pharmaceutical industry is recovering.  

0 Comments

image: Opinion: Parachuting off the Patent Cliff

Opinion: Parachuting off the Patent Cliff

By | December 6, 2012

As the United States edges ever closer to the dreaded fiscal cliff, the pharmaceutical industry approaches a precipice of its own.

4 Comments

image: Hurry Up, FDA

Hurry Up, FDA

By | December 6, 2012

The US Food and Drug Administration is taking steps to get new devices on the market sooner—and antibiotics may be next.

0 Comments

Popular Now

  1. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  2. Does Productivity Diminish Research Quality?
  3. How Plants Evolved Different Ways to Make Caffeine
  4. ESP on Trial
    Foundations ESP on Trial

    In the 1930s, parapsychologist Joseph Banks Rhine aimed to use scientific methods to confirm the existence of extrasensory perception, but faced criticisms of dubious analyses and irreproducible results.

RayBiotech